1 / 6

Authors: Dr. Sunil Verma Date posted: June 22 nd , 2009

Ribbon-1: Randomized, double-blind, placebo, phase III trial of first line chemo with or without bevacizumab for MBC Presented by: N. Robert. Authors: Dr. Sunil Verma Date posted: June 22 nd , 2009. Treatment A: Chemo up to the Investigator

hermione
Download Presentation

Authors: Dr. Sunil Verma Date posted: June 22 nd , 2009

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Ribbon-1: Randomized, double-blind, placebo, phase III trial of first line chemo with or without bevacizumab for MBCPresented by: N. Robert Authors: Dr. Sunil Verma Date posted: June 22nd, 2009

  2. Treatment A: Chemo up to the Investigator ( one of anthracyclines, taxanes or capecitabine) and Placebo R Treatment B: Chemo (as per above) and Bevacizumab 15mg/kg q 3 wk Metastatic Breast Cancer (First Line)

  3. RESULTS Taxane and Anthracyclines

  4. RESULTS Capecitabine

  5. STUDY COMMENTARY • Two (E2100 and AVADO) previous MBC trials have shown that the addition of bevacizumab to first line taxane based chemo led to improvement in PFS, but not OS • This is a placebo controlled trial that shows that addition of Bevacizumab to chemotherapy (either Capecitabine or Anthracline/Taxane) improves PFS • The benefit appeared more pronounced in combination with Capecitabine • About 50-70% of patients received Bevacizumab in the second line setting including those who were in the placebo-arm • There was no statistically significant improvement in OS

  6. BOTTOM LINE FOR CANADIAN MEDICAL ONCOLOGISTS • Health Canada recently approved Bevacizumab in first line treatment of MBC (Feb. 2009) • We need to have better treatment for those who have progressed on Anthracyclines and taxanes in the adjuvant setting. • Capecitabine is increasingly being considered in the first line setting • We still need to define the patient population which derives the most benefit from this drug • The adjuvant study of this class of drugs needs to be done in a defined population with extensive biomarker evaluation

More Related